Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saldan is a finished pharmaceutical formulation of sildenafil citrate, a selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5). Developed and manufactured by Salud Care India Limited, it is primarily indicated for the treatment of erectile dysfunction. Sildenafil works by enhancing the effect of nitric oxide (NO) in the corpus cavernosum; NO activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation and inflow of blood to the penis. By inhibiting PDE5, the enzyme responsible for the degradation of cGMP, sildenafil maintains higher levels of cGMP during sexual stimulation, thereby facilitating penile erection. Saldan is typically administered orally as a tablet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Saldan.